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Presupposti e obiettivi.   
Il diabete mellito (DM) è associato con una alterazione delle cellule pro angiogeniche 
(PACs). Le PACs sono cellule di origine midollare che contribuiscono all’omeostasi 
endoteliale. Il diabete altera le funzioni delle PACs favorendo quindi la disfunzione 
endoteliale. Gli inibitori dell’enzima DPP4, tra cui Saxagliptin (SAXA), sono una classe di 
farmaci usati nella terapia orale antidiabetica del diabete tipo 2. Poichè SDF-1α, chemochina 
coinvolta nella mobilizzazione delle PACs, è un substrato di DPP4, lo scopo dello studio è 
stato testare se l’inibizione di DPP4 possa modificare le capacità funzionali delle PACs. 
 
Metodi. Le PACs sono state isolate da sangue periferico di soggetti sani o diabetici e dopo 
sette giorni di coltura, in terreno addizionato di SAXA e/o SDF-1α, sono stati eseguiti alcuni 
saggi funzionali: adesione ad un monostrato di HUVECs, migrazione, proliferazione, 
tubulizzazione e analisi di espressione genica . 
 
Risultati. L’attività solubile di DPP-4 risulta maggiore rispetto all’attività della forma cellulare 
ed entrambe vengono equamente inibite da Saxagliptin. Al basale le colture di PACs da 
pazienti diabetici rispetto a quelle da soggetti sani contengono meno acLDL+Lectin+ cells e 
mostrano un’espressione alterata dei geni legati all’adesione e alla regolazione del ciclo 
cellulare. Questo rispecchia l’alterata risposta delle PACs da diabetici nei saggi di adesione, 
proliferazione / clono genesi. Saxagliptin + SDF-1α migliora l’adesione e la formazione di 
tubuli da parte delle PACs da soggetti diabetici ma non in quelle da soggetti sani. Le cellule 
da pazienti diabetici che assumono Saxagliptin mostrano una maggiore attivita angiogenica 
in vivo indotta da fattori di crescita rispetto a quelle da pazienti che non assumono 
Saxagliptin. 
 
Conclusioni. Saxagliptin ripristina la funzione delle PACs nel diabete in vitro e migliora 
l’angiogenesi indotta in vivo. Questi dati suggeriscono che l’inibizione di DPP4 possa avere 
un effetto positivo sulle PACs di pazienti diabetici, che potrebbero stimolare la rigenerazione 








Background and aims. Type 2 diabetes (T2D) is associated with reduction and dysfunction 
of circulating pro-angiogenic cells (PACs). PACs are a subset of BM-derived cells that 
contribute to endothelial homeostasis. Diabetes impairs EPC functions, thus prompting 
endothelial dysfunction and cardiovascular diseases. DPP-4 inhibitors, such as Saxagliptin, 
are a relatively new class of antidiabetic agents. Since SDF-1α, a chemokine involved in 
EPC trafficking, is a substrate of DPP-4, we aimed to test whether DPP-4 inhibition affects 
basal and SDF-1α -stimulated EPC function 
 
Methods. PACs were isolated from T2D (n=20) and healthy (n=20) subjects. Gene 
expression, clonogenesis, proliferation, adhesion, migration and tubulisation were assessed 
in vitro by incubating PACs with or without Saxagliptin and SDF-1α. Stimulation of 
angiogenesis by circulating cells from T2D patients treated with Saxagliptin or other non-
incretinergic drugs was assessed in vivo using animal models. Soluble DPP-4 activity was 
predominant over cellular activity and was successfully inhibited by Saxagliptin. At baseline, 
PACs from T2D patients compared to healthy PACs contained less acLDL+Lectin+ cells, and 
showed altered expression of genes related to adhesion and cell cycle regulation. This was 
reflected by impaired adhesion and clonogenesis / proliferative response of T2D PACs. 
Saxagliptin + SDF-1α improved adhesion and tube sustaining capacity of PACs from T2D 
patients, while it did not affect healthy PACs. While Saxagliptin modestly reduced 
angiogenesis by mature endothelial cells, circulating PAC-progeny cells from T2D patients 
on Saxagliptin treatment displayed higher growth factor-inducible in vivo angiogenetic 
activity, compared to cells from T2D patients on non-incretinergic regimen. 
 
Conclusions. Saxagliptin reverses PAC dysfunction associated with T2D in vitro and 
improves inducible angiogenesis by circulating cells in vivo. These data add knowledge to 




LIST OF NON-STANDARD ABBREVIATIONS 
 
APC  Allophycocyanin 
CD  Cluster of differentiation 
CMTMR 5-(and-6)-(((4-chloromethyl)Benzoyl)Amino)tetramethylrhodamine 
DIVAA  Directed In Vivo Angiogenesis Assay  
DPP  Dipeptidyl peptidase 
EBM  Endothelial basal medium 
EGM  Endothelial growth medium 
eNOS  Endothelial nitric oxide synthase 
EPCs  Endothelial progenitor cells 
FGF  Fibroblast growth factor 
FSC  Forward scatter 
GF  Growth factors 
GIP  Glucose-dependent insulinotropic peptide 
GLP  Glucagon-like peptide 
HUVECs Human umbiicanl vein endothelial cells 
MACS  Magnetic activated cell sorting 
PACs  Proangiogenic cells 
PBMC  Peripheral blood mononuclear cells  
PE  Phycoerythrin 
SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with 
Diabetes Mellitus 
SDF  Stromal cell derived factor  
SSC  Side scatter 
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T2D  Type 2 diabetes 
































Diabetes mellitus (DM) is a group of metabolic disorders characterized by a chronic 
hyperglycemic condition resulting from defects in insulin secretion (the body cannot produce 
enough insulin), insulin action (the body cannot use insulin effectively) or both (1). It has 
become an ever-increasing problem throughout the world. International Diabetes Federation 
Diabetes’s most recent estimates indicate that 8.3% of adults – 382 million people – have 
diabetes, and the number of people with the disease is set to rise beyond 592 million in less 
than 25 years (2).   
Diabetes mellitus (DM) is probably one of the oldest diseases known to man. It was first 
recognized around 1500 B.C.E. by the ancient Egyptians, who considered it a rare condition 
in which a person urinated excessively and lost weight. The term diabetes mellitus, reflecting 
that the urine of those affected had a sweet taste, was first used by the Greek physician 
Aretaeus, who lived from about 80 to 138 C.E. It was not until 1776, however, that Matthew 
Dobson actually measured the concentration of glucose in the urine of such patients and 
found it to be increased. Diabetes was a recognized clinical entity when the New England 
Journal of Medicine and Surgery was founded in 1812 (3). 
In the intervening 200 years, major fundamental advances have been made in our 
understanding of the underlying causes of diabetes and the approach to its prevention and 
treatment. Although diabetes is still associated with a reduced life expectancy, the outlook for 
patients with this disease has improved dramatically, and patients usually lead active and 
productive lives for many decades after the diagnosis has been made. Many effective 
therapies are available for treating hyperglycemia and its complications. 
The term diabetes mellitus describes a metabolic disorder of multiple aetiology characterized 
by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both. The effects of diabetes 
mellitus include long-term damage, dysfunction and failure of various organs. Diabetes 
mellitus is subdivided into two groups: type 1 diabetes is immune-mediated and requires 
daily administration of insulin, whereas type 2 diabetes is the most common form and 
comprises of 90% of people with diabetes around the world (World Health Organization). 
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Both type 1 and type 2 cause hyperglycemia, which is the major source of morbidity and 
mortality in diabetes. Hyperglycemia results from the inability of the body to produce and/or 
to properly utilize insulin, the major hormone involved in glucose homeostasis. Type 2 
diabetes is caused by a combination of insulin defect and insulin resistance, the latter being 
also responsible for endothelial dysfunction. Type 2 diabetes results from an imbalance 
between insulin sensitivity and insulin secretion. Under normal physiological conditions, 
plasma glucose concentrations are maintained within a narrow range, despite wide 
fluctuations in supply and demand, through a tightly regulated and dynamic interaction 
between tissue sensitivity to insulin (especially in liver) and insulin/glucagon secretion (4). In 
type 2 diabetes these mechanisms break down, with the consequence that the two main 
pathological defects in type 2 diabetes are impaired insulin secretion through a dysfunction of 
the pancreatic β-cell, and impaired insulin action through insulin resistance (5). 
Insulin is released from pancreatic beta cells in response to a rapid increase in blood glucose 
concentration. In type 2 diabetic patients there is a decreased, and often absent, release of 
insulin than in healthy subjects. Furthermore, beta cell function deteriorates over the years 
following the diagnosis of type 2 diabetes (6). There are several potential causes of beta cell 
dysfunction in type 2 diabetes (7) and in particular one of these is the reduction of beta cell 
mass due to apoptosis.  
Insulin resistance can be defined as the inability of target tissues to respond properly to 
normal circulating concentrations of insulin (8). The main insulin-sensitive tissues are skeletal 
muscle (accounting for 60-70% of whole-body glucose uptake), liver (30%) and adipose 
tissue (10%). To maintain euglycemia, the pancreas compensates by secreting increased 
amounts of insulin. The body’s response to insulin resistance is to enhance the beta cell’s 
secretion of insulin to maintain normal glucose tolerance. As long as the beta cell is able to 
compensate by increasing insulin production, normal glucose tolerance is maintained. The 
final sequence of events is a progressive deterioration in beta-cell function with subsequent 
decline in insulin-secreting ability. 
Although both insulin resistance and impaired insulin secretion precede the development of 
postprandial hyperglycemia and the subsequent type 2 diabetic phenotype, insulin resistance 
is prominent in the prediabetic state and plays an important role in the pathogenesis of 
macrovascular disease. Insulin resistance is commonly the earliest manifestation in the 
development of type 2 diabetes, typically originating 5–10 years before postprandial glucose 
levels in the diabetic range. As long as the beta cell is able to compensate by increased 
insulin production, normal glucose tolerance is maintained.  
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Insulin resistance is characterized by impaired responses to the physiologic effects of this 
hormone on glucose, lipid, and protein metabolism, and by affecting vascular endothelial 
function. The endogenous insulin that is secreted is inefficiently capable of suppressing 
hepatic gluconeogenesis or stimulating glucose uptake and metabolism in the muscle and fat 
(9). Increases in plasma glucose concentrations by 50–100 mg/dL for as little as 24 hours 
can cause downregulation of the glucose transport system in the muscle (GLUT4), 
significantly increasing insulin resistance. Over time, insulin resistance peaks and then 
plateaus as increases in plasma insulin compensate to maintain the glycemic state. 
Hyperglycaemia is a consequence of dysregulated glucose homeostasis. Hyperglycaemia 
becomes diagnostic of type 2 diabetes when secretion of insulin by pancreatic beta cells can 
no longer meet the demand of insulin-resistance for insulin, and undergo cell death as a 
result. In type 2 diabetes, residual insulin secretion may remain, but this is insufficient to 
overcome the tissue’s resistance to insulin. As a consequence of inappropriate or absent 
insulin secretion, glucose is no longer appropriately taken up into target and hepatic 
gluconeogenesis is not inhibited, causing a rise in blood sugar level (10),(11) (Figure 1). 
 
 




The vascular devastation of hyperglycemia can occur by several mechanisms, impacting the 
vessel wall, monocyte-derived macrophages, vascular smooth muscle cells, as well as many 
other cell types. For many years, glycemic control has been a determinate of the micro and 
macrovascular complications from diabetes. The United Kingdom Perspective Diabetes 
Study in type 2 diabetics and the DCCT trial (Diabetes Control and Complication Trial) in 
type 1 diabetics have shown reductions in microvascular and macrovascular complications 
with tighter glycemic control. From these and many other clinical trials the message is clear; 
effective diabetic management including glycemic control reduces complications (12).  
The hallmark of macrovascular disease in the diabetic patient comprises the ugly triad of: 
1. Coronary artery disease and its complications of myocardial infarction and congestive 
heart failure;    
2. Cerebral and carotid arteriosclerotic vascular disease and its complications of stroke 
and cerebral ischemia;                                    
3. Peripheral vascular disease and its complications of claudication, ischemia, and 
amputation  (13). 
The microvascular complications of diabetes include: Retinopathy, Nephropathy, 
Neuropathy. Most people with diabetes develop at least some form of eye disease 
(retinopathy), which can damage vision or provoke blindness. Persistently high levels of 
blood glucose, together with high blood pressure and high cholesterol, are the main causes 
of retinopathy. The network of blood vessels that supply the retina can become blocked and 
damaged in retinopathy, leading to permanent loss of vision. The most advanced stages of 
retinopathy can be managed through regular eye checks and by keeping blood glucose 
levels close to normal.  
Kidney disease (nephropathy) is far more common in people with diabetes than in people 
without diabetes; and diabetes is one of the leading causes of chronic kidney disease. The 
disease is caused by damage to small blood vessels and epithelial cells, which can cause 
the kidneys to be less efficient, or to fail altogether. Maintaining near-normal levels of blood 




When blood glucose and blood pressure are excessively high, diabetes can provoke damage 
to nerves throughout the body (neuropathy). This damage can lead to problems with 
digestion and urination, erectile dysfunction and a number of other functions. The most 
commonly affected areas are the extremities, particularly the feet. Nerve damage in these 
areas is called peripheral neuropathy, and can lead to pain, tingling, and loss of feeling. Loss 
of feeling is particularly dangerous because it can allow injuries to go unnoticed, leading to 
serious infections and ulceration, diabetic foot disease, and major amputations Neuropathy,  
includes mononeuropathy, diabetic amyotrophy, symmetric distal neuropathy, diabetic 
gastroparesis, diabetic diarrhea, neurogenic bladder, impaired cardiovascular reflexes, and 
sexual dysfunction (14). People with diabetes may develop a number of different foot 
problems as a result of damage to nerves and blood vessels. These problems can easily 
lead to infection and ulceration, which increase a person’s risk of amputation. People with 
diabetes face a risk of amputation that may be more than 25 times greater than that in 
people without diabetes (15). However, with good management, a large proportion of 
amputations can be prevented.  
Hyperglycemia is the major causal factor in the development of endothelial dysfunction in 
patients with diabetes mellitus. Clinical trials have identified hyperglycemia as the key 
determinant in the development of chronic diabetic complications (16). Over the past 35 
years, four seemingly independent major mechanisms of hyperglycemia-induced damage 
have been proposed to explain how hyperglycemia directly causes diabetic vascular 
complications. An increase in intracellular glucose will lead to an increase in the efflux of 
glucose to sorbitol via the polyol pathway and the activation of PKC C (protein kinase C) via 
de novo synthesis of DAG (diacylglycerol). In addition, glucose and glucose derived 
dicarbonyl compounds react non-enzymatically with the basic amino acids lysine and 
arginine in proteins to form AGEs (advanced glycosylation end-products) both extra- and 
intra-cellularly. These different pathways are interrelated and potentiate each other. Each of 
these mechanism has been studied independently of the others, and there has been no 
apparent common element linking them. Brownlee’s research has established that these 
biochemical pathways all arise from a single hyperglycemia-induced process: the 
overproduction of toxic free radicals produced by mitochondria. Brownlee’s unifying 
hypothesis considers that the oxidative stress launched by mitochondria is a common 
pathogenesis of chronic diabetic complications (17). He has also demonstrated that 
normalizing the levels of these excess free radicals inhibits the pathways through which cell 
damage occurs, and that all of these pathways can be activated, even in the presence of 
normal glucose levels, simply by using molecular genetic techniques to shut down the key 
enzyme that high glucose turns off. Figure 2 shows how, intracellularly, these four 
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biochemical mechanisms may all be the consequence of hyperglycaemia-induced 
overproduction of ROS in mitochondria (18). 
 
 
Figure 2. Potential mechanisms by which hyperglycaemia and  its  immediate biochemical  sequelae  induce 
hyperglycaemic damage (source: Diabetes ©2003 American Diabetes Association,Inc.). 
Endothelial dysfunction has received increasing attention as a potential contributor to the 
pathogenesis of vascular disease in diabetes mellitus; in fact it is a common finding in type 2 
diabetic patients. Under physiological conditions, there is a balanced release of endothelial-
derived relaxing and contracting factors, but this delicate balance is altered in diabetes and 
atherosclerosis, thereby contributing to further progression of vascular and end-organ 
damage (19). Over the last two decades it has become evident that the endothelium is not an 
inert, single-cell lining covering the internal surface of blood vessels, but in fact plays a 
crucial role in regulating vascular tone and structure. Importantly, a healthy endothelium 
inhibits platelet and leukocyte adhesion to the vascular surface and maintains a balance of 
profibrinolytic and prothrombotic activity (20). 
Endothelial cell dysfunction is a broad term which refers to a condition in which the 
endothelium loses its physiological properties. Normally, the endothelium actively regulates 
vascular tone, limits leucocyte adhesion and thus inflammatory activity in the vessel wall, 
maintains vascular permeability to nutrients, hormones, other macromolecules and 
leucocytes, inhibits platelet adhesion and aggregation by producing prostacyclin and NO, 
limits activation of the coagulation cascade by the thrombomodulin/protein C, heparan 
sulphate/antithrombin and tissue factor/tissue factor pathway inhibitor interactions, and 
regulates fibrinolysis by producing t-PA and its inhibitor PAI-1 (18). 
 15 
 
 Several factors contribute to the dysregulation of endothelial cell functions,  including 
smoking, high blood pressure, high cholesterol, obesity, hyperglycemia, advanced glycation 
end products (AGEs), and genetic factors (21). As such, abnormalities in endothelial function 
are detected early in the development of CVD, often before symptoms are clinically evident 
(22). Dysfunction of the vascular endothelium is regarded as an important factor in the 
pathogenesis of micro- and macroangiopathy (23) and endothelial function has gained 
increasing attention in the study of vascular disease. A considerable body of evidence in 
humans indicates that endothelial dysfunction is closely associated with the development of 
diabetic retinopathy, nephropathy and atherosclerosis in both type 1 and type 2 diabetes 
(24). 
 
Endothelial progenitor cells 
Diabetes is associated with defects in angiogenesis or in vessel repair (figure 3). Angiopathy 
is the term for vascular defects associated with angiogenic abnormalities. These include 
abnormally enhanced angiogenesis, defined as capillary vessel growth in the retina (25) 
leading to diabetic retinopathy (26) and insufficient angiogenesis implicated in abnormal 
wound healing, leading to diabetic skin ulcers  (27).  
Interestingly, EPC decrease is related to peripheral arterial disease severity, strengthening 
the pathogenetic role of EPC dysregulation in diabetic vasculopathy (28). 
The decrease in the number of angiogenic cells may also be because of the diabetes 
mellitus–induced abrogation of BM-derived cell mobilization. Hence, in control rats, EPCs 
showed a 
mobilization curve within 7 days, whereas diabetic rats are completely unable to mobilize 
EPCs after ischemic injury. As a consequence, diabetic rats show no compensatory increase 
in muscle capillary density. Defective EPC mobilization in diabetes mellitus is associated with 
altered release of CXCL12 and VEGF and inability to upregulate muscle HIF-1α (29). 
Wound healing capacity in diabetic patients is decreased. The normal process of wound 
healing is characterized by five sequential processes: (a) hemostasis, (b) inflammation and 
debridement, (c) proliferation, (d) epithelialization, and (e) remodeling (30). The delayed 
wound healing in diabetic patients has been attributed to disturbances in the 
inflammation/debridement and proliferation phases (31). In the wound healing process, 
microangiopathy may also contribute to defects in the nutrient/oxygen supply, thus inhibiting 
normal healing processes (32). Both clinical research and animal models have confirmed 






mellitus.  Defective  VEGF  signaling  results  in  impaired  Flk‐1  activation  that  affects  a  number  of  processes 
thought  to  be  involved  in  arteriogenesis,  including  endothelial  cell  growth  and  migration,  monocyte  and 
endothelial progenitor cell (EPC) recruitment, and EPC release by the bone marrow. As a result, arteriogenesis 
is  impaired. At the same time, decreased VEGF sensing, due to  impaired Flk‐1 activation, results  in  increased 
serum VEGF  levels  that  lead  to pathologic angiogenesis  (retina, atheroma). AGE: advanced glycosylated end‐
products. .(Journal of the American College of Cardiology Vol. 46, No. 5, 2005) 
 
Since the 1930s repair of the damaged endothelium was thought to occur by the migration 
and proliferation of neighboring undamaged endothelial cells (ECs), and the regeneration of 
new blood vessels was believed to be mainly through the sprouting of ECs.  
In 1997, Asahara and colleagues reported (34) that some circulating blood cells possessed 
the potential to differentiate in vitro into adherent cells displaying cell surface antigens typical 
for endothelial cells and simultaneous loss of many typical hematopoietic markers. The cells 
displaying these proprieties were called circulating endothelial progenitor cells (EPCs). It is 
now known that EPCs originate in the bone marrow and contribute to the formation of new 
blood vessels in adults. The discovery of EPCs overturned the belief by which in the adult, 
vascular growth and remodelling was exclusively dependent on the activation of 
angiogenesis, being the process of vasculogenesis restricted to embryonic life (35). Their 
discovery led to the new concept that vasculogenesis and angiogenesis may occur 
simultaneously in the postanatal life because these cells are able to differentiate when 
needed into vascular endothelium, through a mechanism recapitulating embryonic 
vasculogenesis (36). They play important roles in vascular regulation at homeostasis and 
initiation of neoangiogenesis during wound healing, tissue ischemia, tissue remodelling, and 
tumorigenesis without becoming an integral part of the endothelial intima. 
Angiogenesis is the process by which new blood vessels take shape from existing 
vasculature by sprouting of endothelial cells and before 1997 angiogenesis was considered 
responsible for most, if not all, blood vessel growth (37). Recent studies have shown that a 
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mechanism different from angiogenesis exists for formation of vessels in adults called 
postnatal vasculogenesis or neovascularisation. 
Vasculognesis is the process of new blood vessel formation during embryonic development. 
This process involves the de novo formation of blood vessels by the differentiation of 
precursor cells into endothelial cells (EC), which eventually give rise to capillaries. This is the 
reason why the discovery of bone marrow (BM)-derived EPCs with angioblastic 
morphological and functional properties was a landmark in vascular biology that forever has 
changed the concept of neovascularization. Increasing evidence suggests that EPCs 
functionally contribute to the formation of new blood vessels in several models of tissue injury 
and remodelling, including wound healing, myocardial ischemia, retinopathy, stroke, 
peripheral vascular disease. 
The definition and characteristics of EPCs are a work in progress. EPCs are believed to 
differentiate from hemangioblasts along with other hematopoietic stem cells. Progenitor cells 
have been distinguished from stem cells due to the lack of self-renewing ability. However, 
EPCs are characterized as lineage-committed adult stem cells, as they have some degrees 
of stemness, including self-renewal, clonogenicity, and differentiation capacity.  
In order to isolate and quantify EPCs one can use two approaches: in vitro adhesion and 
growth and selection by cell surface phenotype using fluorescent-labelled antibodies and 
flow cytometry. 
In the human system, putative EPCs have been isolate and identified using three general 









Figure 4.  Common methods  of  EPC  culture.  Culture  of  colony‐forming  unit  –  endothelial  cells  (CFU‐EC, 
Method A,  scale bar=100 mum)  includes  a 5‐day process wherein non‐adherent MNCs  give  rise  to  the EPC 
colony. Circulating angiogenic cells (CAC, Method B, scale bar=200 mum) are the adherent mononuclear cells of 
a 4‐  to 7‐day  culture procedure. CAC  cultures  typically do not display  colony  formation. Endothelial  colony‐
forming cells (ECFCs, Method B, scale bar=400 mum) are derived from adherent MNCs cultured for 7–21 days 
in  endothelial  conditions  and  colonies  display  a  cobblestone morphology.  (Working  hypothesis  to  redefine 
endothelial progenitor cells. D N Prater, J Case, D A Ingram and M C Yoder) 
 
The first involves collecting low density mononuclear cells (MNCs) from human peripheral 
blood  and preplating them for 48 hours on fibronectin coated dishes and then replating the 
nonadherent cells to quantify the emegerce of the EPC colony forming units several days 
later. The putative EPCs have been referred to as colony forming unit-Hill (CFU-Hill). These 
CFU-Hill appearing colonies are composed of round hematopoietic cells that include myeloid 
progenitor cells, monocytes and T lymphocytes (38; 39).  
A second method is based on adhesion of peripheral blood mononuclear cells to fibronectin-
coated culture dishes was described by Vasa et al in 2001 (40; 41). Mononuclear cells from 
peripheral blood were plated on fibronectin and gelatine coated dishes in the presence of 
media supplemented with endothelial growth factors and fetal calf serum. After 4 days in 
culture, the non adherent cells where removed, and the adherent cells were assessed for the 
ability to ingest acetylated low density lipoprotein (LDL) or fluorescent labelled Ulex 
europaeus agglutinin 1 plant lectin. Many studies suggest that direct adhesion of peripheral 
blood mononuclear cells to fibronectin coated dishes may enrich for monocytes and is 
certainly not specific for EPCs. Whether or not the monocytes isolated in this manner, 
proceed to express endothelial specific markers and participate in angiogenesis depends on 
the culture conditions and growth factors used. This fact in particular has led to some 
confusion, since some investigators suggested that monocytes become EPCs. A more 
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plausible working hypothesis is that some monocytes-macrophage subsets are potent 
circulating regulators of the angiogenic response and have been called CAC, circulating 
angiogenic cells. They play important roles in vascular regulation at homeostasis and 
initiation of neoangiogenesis during wound healing, tissue ischemia, tissue remodelling, and 
tumorigenesis without becoming an integral part of the endothelial intima (42-45). 
The clusters or colonies of cells that emerged from the previous methods were referred to as 
early outgrowth colonies. 
Another different population of cells has been determined to emerge later in culture and at 
were referred to as late outgrowth colonies. The early outgrowth cells have largely been 
proved to be hematopoietic cells, the later outgrowth cells are clearly endothelial cells.  
A different method of human EPC identification has relied on identification of a particular 
pattern of cell surface antigen expression on the cells. There are no unique or specific 
protein markers that can be used to prospectively isolate an EPC (46). In 1997, Asahara et 
al. reported the isolation of putative EPC from human peripheral blood, on the basis of cell-
surface expression of CD34 and other endothelial markers (36). 
In fact EPCs were initially described as a pool of circulating bone marrow derived CD34+ 
progenitor cells that display vasculogenic potential (47; 48). The choice of CD34 as a 
potential marker of the circulating angioblast was not surprising as it is known to be 
expressed on endothelial cells and is a marker used to isolate human hematopoietic stem 
and progenitor cells for clinical stem cell transplantation (49). Circulating EPCs originate 
primarily from the bone marrow and can be identified by differential expression of 
hematopoietic and endothelial cell markers. This is important because HSCs and EPCs 
probably share a common precursor, the hemangioblasts (50). Hemangioblasts reside 
mainly in the bone marrow and differentiate into HSCs and angioblasts. This process occurs 
mainly during early embryogenesis but was shown to exist in adults angioblasts will give rise 
to EPCs that upon stimulation with angiogenic factors are mobilized from bone marrow to 
peripheral blood (51; 52).  
CD34 is a sialomucin expressed on a variety of mesoderm progeny including blood 
endothelial and fibroblasts and by numerous epithelial lineages and some cancer stem cell 
population (46). Thus, use of CD34 as an individual EPC marker is inadequate and would 
certainly require the search for additional potentially unique markers to discriminate all these 
different cellular lineages from the putative EPCs.  
For this reason, EPC linage was characterized via the expression of another hematopoietic 
marker, a 120 kDa glycosilated polypeptide, with 5 transmembrane-domains, CD133 (initially 
called AC133) (53). CD133 expression defines a very early population of progenitor cells, 
immature HSCs, in which the two sub-fractions of adult bone-marrow stem cells (the 
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hematopoietic and the mesenchymal subset) seem to be represented. CD133, is a highly 
conserved antigen with unknown biological activity, which is expressed on hematopoietic 
stem cells but is absent on mature endothelial cells and monocytic cells. EPCs have the 
capacity to proliferate, migrate and differentiate into endothelial lineage cells, but have not 
yet acquired characteristics of mature EC.   
Since MNC are heterogeneous, other studies have tried to better define the EPC 
characteristics. EPCs should express CD34, CD133 and VEGF receptor-2 (VEGFR-2), also 
known as flk-1 or KDR. Recent studies have shown that also cells expressing CD14 antigen 
(monocytes/macrophages) (54) can effectively participate to neovasculogenesis, either CD34 
negative or CD133 negative (55). Despite the different subpopulation characteristics, also 
these cells show analogue vasculogenic abilities (56) suggesting that EPCs represent a 
heterogeneous group at various differentiation stages.  
Nowadays a unique definition of EPCs does not exist despite significant steps forward have 
been taken in order to reach a better definition and a detailed functional characterization of 
these cells. This may reflect that the endothelial progenitor is a dynamic phenotype in space 
and time. Indeed, the endothelial differentiation potential of circulating progenitors varies 
according to the local environment and changes over time, as can be recapitulated in the 






Functional Characteristics of EPCs. 
Typical functions of EPCs in vitro are proliferation and clonogenesis, migration, adhesion, 
and tubulisation. An important functional characteristic is the capacity to form cord- and 
tubular-like structures in three-dimensional gels, like Matrigel (58), as mature endothelial 
cells do. Additionally, migratory capacity of EPCs is typically tested in vitro. A commonly 
used characterization of endothelial differentiation is based on EPC functions of uptaking 
acetylated low density lipoproteins (AcLDL) and binding lectin, Ulex europaeus agglutinin-1 
(UEA-1). While ac-LDL uptake is dependent on scavenger receptors common to monocytes, 
UEA-1 binding is considered more specific for endothelial cells. Several functions of EPCs 
can also be established in vivo, such as formation of new blood vessels in relevant models in 
the laboratory animal. 
Mobilization and homing of EPCs. 
Several groups have demonstrated a significant restoration of blood flow and enhanced 
tissue regeneration after administering bone marrow-derived cells or EPCs after an ischemic 
event (59). The process whereby EPCs participate to postnatal vasculogenesis consists of 
four interrelated steps: mobilization, homing, invasion and differentiation into mature ECs 
and/or regulate preexisting ECs via paracrine or juxtacrine signals. The mobilization of EPCs 
from the bone marrow (BM), in order to re-estabilish an intact endothelial layer following 
denudation of endothelium, is a complex process. It is known that the majority of EPCs 
remain quiescent in the stem cell niche in the BM, which consists of fibroblasts, osteoblasts, 
mesenchymal cells, adipocytes, and endothelial cells. The BM niche is characterized by low 
oxygen tension and high levels of stromal cell derived factor-1α (SDF-1α) or CXC chemokine 
ligand 12 (CXCL12).  Many studies have indicated that SDF-1α is a potent factor in 
mobilizing primitive progenitors from the BM niche (60; 61). SDF-1α, is a 7.97-kDa 
chemokine and is known to be an effective chemotactic factor for a variety of cell types that 
contains the G protein – linked receptor CXCR4. SDF-1 is produced constitutively in many 
organs, including BM, spleen, heart, liver and kidney; it plays a vital role in organ 
homeostasis, retention of HSCs and progenitors within the BM, and general development. In 
vivo stem cell homing to the BM, their retention, engraftment, and egress to the circulation, 
all involve SDF-1/CXCR4 interactions. In fact  SDF-1α chemoattracts normal CD34+ CXC 
chemokine receptor-4 (CXCR4)- positive early hematopoietic cells (62). CXCR4 is the 
predominant receptor for SDF-1 α  and the cross–talk between CXCR4+ EPC and SDF-1α-




Under homeostatic conditions, most progenitors remain in the BM compartment, where they 
are retained by high SDF-1α expression induced by the hypoxic microenviroment. It is 
possible that low numbers of progenitor cells continuously recirculate under physiologic 
conditions (64). During alarm situations, stress, and injury, progenitor cell egress to the 
circulation is dramatically increased. This process is termed mobilization.    
Tissue ischemia is considered the strongest stimulus for EPC mobilization, through the 
activation of hypoxia-sensing systems, such as hypoxia-inducible factor (HIF)-1. HIF-1 is a 
heterodimeric transcription factor composed of α (HIF-1α) and β (HIF-1β) subunits. While 
HIF-1β is constitutively expressed, HIF-1α expression is regulated by cellular oxygen 
concentrations. Under normoxic conditions, HIF-1α is rapidly degraded via the ubiquitine-
proteasome pathway, while cellular hypoxia inhibits its ubiquitination and proteasomal 
degradation, allowing HIF-1α to dimerize with HIF-1β. The resulting active HIF-1 binds to 
enhancer DNA regions and promotes the transcription of oxygen-sensible genes that 
encode, among others, vascular endothelial growth factor (VEGF), SDF-1α, and 
erythropoietin (65).  
There is a direct correlation between the plasma concentration and degree of mobilization, 
implying a concentration gradient determines response (66). After an ischemic insult, soluble 
factors, such as SDF-1α, are released by injured tissue and stimulate mobilization of 
progenitor cells from the BM. SDF-1α is selectively upregulated in transiently ischemic tissue 
guiding the recruitment of progenitor cells to a permissive or conditional niche, where they 
proliferate and assemble. Progenitor cells are recruited to ischemic tissue by high local levels 
of SDF-1α providing a permissive niche. During condition of ongoing local tissue hypoxia, 
progenitor cells proliferate and assemble into vascular structures, contributing to the 
remodeling of nascent vascular network, and eventual reoxygenation of the tissue. After 
neovascularization tissue oxygenation returns to normal levels, SDF-1α expression returns to 
baseline, and progenitor cell recruitment stops.  
The dependence of progenitor cell recruitment and function on a hypoxic microenvironment 
suggests that targeting the hypoxic response mediated by the transcription factor HIF-1α 
may be a more rational strategy for achieving therapeutic angiogenesis in patients with 
congestive heart failure. 
Recently, Rajagopalan and colleagues reported the first clinical results of HIF-1α gene 
therapy predicated on transcriptional activation of a patient's own gene. The high dose of 
HIF-1α gene therapy improved therapeutic outcomes in critical limb ischaemic patients. More 
importantly, it appears to be safe for clinical application (67). In fact, HIF-1α overexpression 
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on EPCs promotes hypoxia-induced EPC differentiation, proliferation and migration, (68) 
establishing HIF-1α  as a putative pharmacological target. 
 
Figure 5. Schematic  representation  of mobilization  of  endothelial  progenitor  cells  (EPC)  from  the  bone 
marrow.  Br J Clin Pharmacol. Oct 2009; 68(4): 484–492. 
 
The figure 5 shows as the cells mobilization is a result of high levels of circulating SDF-1α, 
that appear to reverse the SDF-1α gradient across the BM barrier, forcing CXCR4+ cells to 
exit the BM (69). In other words EPCs are mobilized from the BM in response to peripheral 
tissue hypoxia and trauma, which cause the production and release of EPC-activation 
factors, such as HIF-1a (70), vascular endothelial growth factor (VEGF), erythropoietin 
(EPO), estrogens, or SDF-1α to a concentration greater than that in the BM (56). SDF-1α  
cleavage in the BM is postulated as a crucial process, breaking anchorage of stem cells to 
endosteal stroma and osteoblasts or vascular endothelium, shown to comprise the stem cell 
niche (71; 72),(73). Moreover, quiescence and immobility signals exerted by SDF-1α, which 
has been shown to maintain stem cells in their niche, are now disrupted. The mobilizing 
effect initiated by reversing the SDF-1α gradient was demonstrated by direct elevation of 






Throughout  stress and  inflammation conditions,  the expression of SDF‐1α  is  increased  in  the  injured organs 
and  consequently  in  the  peripheral  blood.  Circulating  SDF‐1α  is  internalized  by  CXCR4  (1and  2)  across  the 
physiologic  blood  vessel  barrier  (3)  into  the  BM  (4)  where  it  binds  CXCR4  in  the  stem  cell  niche  (5).  (B) 
Presentation  of  translocated  SDF‐1α  by BM  endothelial  and  other  stromal  cells  recruits  circulating  CXCR4D 




Figure 7.  Molecular mechanism regulating the multiple steps of endothelial progenitor cell biology during 
postnatal vasculogenesis. Recruitment and  incorporation of EPCs  into angiogenic sites requires a coordinated 
multistep  process  including mobilization,  chemoattraction,  adhesion,  endothelial  transmigration, migration, 
tissue  invasion,  in situ differentiation and paracrine and/or  juxtacrine factor production. The major molecular 
mechanisms that have been implicated in the distinct steps of EPC biology are indicated. Figure adapted from 





The egress of stem cells from the BM is allowed by the activation of proteases such as 
elastase, cathepsin G, and matrix metalloproteinases (MMPs), which cleave adhesive bonds 
on stromal cells, and interact with integrins on hematopoietic stem cells (74) (Figure7).  
Once mobilized, EPCs are released from the vascular zone of the BM into the peripheral 
circulation. To date, no clear definition exists as to when a circulating EPC turns into a 
mature, fully differentiated endothelial cell in vivo. An initiation of this differentiation may by 
the migration of EPCs from the BM into the peripheral circulation and after adhesion and 
insertion into the monolayer of surrounding mature endothelial cells this differentiation 
process may be completed. However, the exact differentiation cascade of EPCs in vivo is 
hardly comprehensible. Circulating EPCs can contribute to vascular repair not only by direct 
transdifferentiation into vascular endothelial cells but also and in particular via the secretion 
of proangiogenic cytokines. 
Adhesion molecules of the selectin and integrin family are also essential for EPC arrest to 
endothelial cells. Chemokines have been shown to trigger integrin activation to mediate 
arrest of rolling leukocytes. Isolated human EPCs demonstrate significantly increased and 
constitutive adhesion on the β2-integrin ligands fibrinogen and ICAM-1 under physiological 
flow conditions in vitro (75). Functionally active β2-integrins further mediated arrest of EPCs 
to mature endothelial cells and their subsequent emigration into tissues, implying the 
importance of this integrin subclass not only after arterial injury but also during angiogenesis 
in ischemic regions, where sprouting of newly formed capillary structures is required. The 
association of β2-integrins with the homing of hematopoietic progenitor cells (including also 
EPC populations) during neovascularization was demonstrated in a mouse model of hind 
limb ischemia (75). In addition to β2-integrins, β1- integrins have also been involved in the 
homing of BM-derived progenitor cells to the remodeling vasculature. The α4β1 integrin (also 
known as very late antigen-4, VLA-4) plays an important role in EPC homing. Blockade of 
VLA-4 significantly reduces the in corporation of CD34+ cells to areas of active tumor 
vascularization, and, recent data revealed a critical involvement of VLA-4 in the homing of 
human EPCs to ischemic tissue (76). Vascular cell adhesion molecule (VCAM) and 
fibronectin are well known ligands for VLA-4. While VCAM is primarily upregulated in 
ischemic tissue, interaction of VLA-4 with fibronectin occurs mainly when denuded vascular 
ECM is exposed to the blood flow, e.g. after endothelial injury. It is conceivable that coating 
of biomaterials with EPC attracting compounds may be helpful for tissue engineering. Local 
delivery of VEGF-A within a region of endothelial denudation, e.g. after stent implantation, 
may be helpful to selectively attract EPCs and to achieve stent endothelialization, but has to 
be scrutinized with caution in the context of advanced atherosclerosis due to the risk of 
plaque destabilization. Finally, coating strategies with antibodies against progenitor cell 
 26 
 
antigens (e.g. CD34) were reported to effectively accelerate endothelialization by capturing 






EPC alterations in diabetes. 
Traditionally, the development of diabetic complications has been attributed to the 
biochemical pathways driving hyperglycaemic cell damage, while reparatory mechanisms 
have been long overlooked. A more comprehensive view of the balance between damage 
and repair suggests that an impaired regenerative capacity of bone marrow (BM)-derived 
cells strongly contributes to defective re-endothelisation and neoangiogenesis in diabetes 
(77). It can therefore be predicted that defects in the mechanisms of repair can worsen, and 
hence vascular disease can be accelerated, in patients subjected to vascular noxae. Several  
lines of evidence indicate that diabetes should indeed be considered a disease of impaired 
damage control (78)  with defects in the regenerative pathways that normally follow tissue 
injury. 
Numerous studies have demonstrated an effect of hyperglycaemia on EPC biology. Culturing 
EPCs derived from healthy subjects under high glucose conditions impaires EPC number 
and function (79). If cultured in high glucose conditions, these cells present impaired function 
and decreased nitric oxide and MMP-9 production (80).  
Both cytometric and culture methods have extensively demonstrated that type 1 and type 2 
diabetic patients have less circulating EPCs than matched healthy subjects. Moreover, 
diabetic EPCs display functional impairment, such as reduced proliferation, adhesion, 
migration, and incorporation, into tubular structures (81). The reduction of the circulating 
CD34+ progenitor cell pool (the ancestor of all EPC phenotypes) occurs at an early stage in 
the natural history of type 2 diabetes and can be demonstrated in individuals with impaired 
glucose tolerance (82). The depletion of progenitor cells persists over time and is worse in 
patients with advanced complications (81),(83). Indeed, the levels of CD34+KDR+ EPCs are 
strongly negatively correlated to the degree of peripheral vascular complications in type 2 
diabetes (28). The link between hyperglycaemia and altered EPCs is strongly supported by 
studies in type 1 diabetes. Type 1 diabetes causes early EPC dysfunction that is quite similar 
to that observed in type 2 diabetes (84). 
These observations suggest that the burden of DM-related cardiovascular complications 
correlates with the number and function of EPCs: alterations in EPCs may contribute to the 
development and progression of atherosclerosis in patients with type 2 DM (85).The  
reduction in circulating EPCs in diabetic patients may recognize at least three 
pathophysiological explanations: impaired BM mobilization, defective proliferation, and 
enhanced apoptosis. Remarkably, in accordance with Brownlee's unifying hypothesis, 
oxidative stress appears as a major determinant of all of these mechanisms (86).  
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Experimental (87),(77) and human (88) studies also demonstrate that DM impairs the 
mobilization of EPCs in response to tissue ischemia or cytokines, such as granulocyte colony 
stimulating factor.  
The migration of EPCs to sites of injury/ischemia is mediated by the gradient of SDF-1α and 
other chemoattractans, such as VEGF. In addition to the altered cytokine gradient, 
decreased NO, increased reactive oxygen species, and advanced glycation end products in 
DM impair this migration. These pathological processes induced by diabetes also increase 




(BM)  progenitor  cells  and  their mobilization  are  reduced  because  of  the  alteration  in  the  osteoblastic  and 
vascular niches and  the  cytokines profiles,  respectively, and  the  survival of  circulating EPCs  is  reduced. As a 
result,  the  numbers  of  circulating  EPCs  are  decreased  in  subjects  with  DM.  Furthermore,  the  migratory, 
recruitment, and angiogenic  functions of EPCs at  ischemic  tissue  in subjects with DM are  impaired and  thus 
contribute to defective vascular repair and angiogenesis. (ATVB .2014;34:1136-1143). 
 
In patients with DM, the high glucose environment reduces the level of VEGF and SDF-1α 
secretion from endothelial cells via the hypoxia-inducible factor/ hypoxia-responsible element 






Dipeptidyl peptidase-4  
Because-impaired glucose metabolism and hyperglycemia are the primary initiating events 
that induces EPC alteration in DM, and EPC dysfunction is closely related to the degree of 
hyperglycemia, improved hyperglycemic control should be the initial therapeutic target. 
Currently, there are only limited data on the optimal antidiabetic therapy to reverse EPC 
dysfunction in DM. For type 2 diabetes the oral medication can be subdivided in these 
classes: 
 
- Biguanide, metformin is the only member of the class and it is one of the oldest medications 
used in the treatment of type 2 diabetes. Metformin exerts its effects primarily by decreasing 
hepatic glucose output and has a comparatively lesser effect increasing insulin sensitivity. 
- Sulfonylureas. This class include several medication that act on beta-cells to increase 
insulin release. They bind to the sulfonylurea receptor on the surface of the β-cell and inhibit 
potassium efflux, thus depolarizing the β-cells and facilitating insulin release. First-generation 
agents, such as acetohexamide, chlorpropamide, and tolbutamide have been replaced by 
second- and third-generation sulfonylureas, such as glyburide, glipizide, gliclazide and 
glimipiride. 
- Glinides. The glinides, nateglinide and replaginide, exert their effects in a manner similar to 
sulfonylreas, by binding to the sulfonylurea receptor and inducing depolarization of the β-
cells. However, they bind in a different manner to the sulfonylurea receptor and have a 
shorter half-life. 
- Thiazolidinediones. The thiazolidinediones rosiglitazone and pioglitazone are insulin 
sensitizers. These drugs bind to peroxisome proliferator-activated receptors (PPARs) in cells, 
and this drug-PPAR complex (with one or more coactivators) acts on response elements in 
promoter regions to affect the transcription of as many as 100 genes. 
- Alfa-glucosidase inhibitors. Acarbose and miglitol are the α-glucosidase inhibitors currently 
available in clinical practice. They act by inhibiting the intestinal enzyme that cleaves 
polysaccharides into monosaccharides, thereby limiting intestinal glucose absorption.  
- GLP-1 receptor agonists, which promote glucose-induced insulin secretion. 
- Dipeptidyl peptidase-4 (DPP4) inhibitors. DPP-4 inhibitors are a relatively new class of oral 
agents for the treatment of type 2 diabetes. They act by inhibiting the enzymatic degradation 
of glucagon-like peptide 1 (GLP-1), thereby potentiating glucose-induced insulin secretion 
after a meal.  
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Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-
cell activation antigen CD26 (EC 3.4.14.5) is a serine exopeptidase that cleaves X-proline 
dipeptides from the N-terminus of polypeptides (Figure 9), such as chemokines, 
neuropeptides, and peptide hormones. DPP4 is a type II transmembrane glycoprotein, 
expressed on the surface of many cell types, whose physiological functions are largely 
unknown. The enzyme exists as a membrane-anchored cell surface peptidase and as a 
second smaller soluble form present in the circulation. The soluble circulating form of DPP-4 
(sDPP-4) that lacks the transmembrane and cytoplasmic domains of mDPP-4 is largely 
responsible for degradation of the majority of newly synthesized GLP-1 and GIP  
(89),(90),(91). 
Evidence suggests that proteolytic cleavage of membrane membrane-associated DPP-4 
(mDPP-4)  is the major source of circulating sDPP-4 (92). DPP4 family consists of several 
members: DPP4, quiescent cell proline dipeptidase (QPP), fibroblast activation protein 
(FAP), DPP8 and DPP9. (93) DPP4 is widely expressed (lung, brain, pancreas, kidney, 
vessel, prostate, uturus, thymus, lymph nodes and spleen) on the cell surface of cells 
including epithelial, endothelial cells and immune cells such as natural killer (NK)cells, 
lymphocytes and monocytes. (93). The enzyme cleaves a diverse range of proteins including 
glucagon-like peptide (GLP)-1 and 2, glucose-dependent insulinotropic peptide (GIP), 









Both GLP-1 and GIP are gastrointestinal (Gut) hormones (incretins), secreted after ingestion 
of nutrients. Gut hormones are synthesized by specialized enteroendocrine cells located in 
the epithelium of the stomach, small bowel and large bowel and are secreted at low basal 
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levels in the fasting state. Plasma levels of most gut hormones rise briskly within minutes of 
nutrient intake and fall rapidly thereafter, mainly because they are cleared by the kidney and 
are enzymatically inactivated (94). 
Incretins are involved in multiple functions and in particular they facilitate the disposal of 
glucose trough the stimulation of insulin secretion from the endocrine pancreas. In 1932 La 
Barre proposed the name "incretin" for these hormones. The term incretin effect was used to 
describe the fact that oral glucose load produces a greater insulin response than that of an 
isoglycemic intravenous glucose infusion (95). The observation that GLP-1 is rapidly 
degraded by DPP-4 has fostered the development of specific protease inhibitors that prevent 
the rapid fall of GLP-1 in circulating plasma after eating (96). By 1995 DPP-4 inhibition was 
under consideration for the treatment of diabetes.   (97). Sitagliptin, from Merck and Co., was 
the first DPP-4 inhibitor to be approved by the U.S. Food and Drug Administration in October 
2006. Nowadays DPP-4 inhibitors are a class of anti hyperglycemic agents indicated for 
improving glycemic control in patients with type 2 diabetes. 
In addition to incretins, DPP-4 has several other physiologic substrates, including cytokines, 
chemokines, and neurohormones that can affect vascular function and metabolism. For 
exemple the figure 10 shows that DPP-4 cleaves multiple peptides which are capable of 







Interestingly, SDF-1α is a natural DPP-4 substrate and a major regulator of stem cell 
mobilization,(98) as well as EPCs / PACs function (67; 99) . Both GLP-1 and SDF-1α have 
been shown to increase the number of circulating EPCs and improve endothelial function 
(100; 101) which suggests that DPP-4 could be a possible candidate for pharmacotherapy in 
therapeutic vasculogenesis.  
In patients with type 2 diabetes or chronic hyperglycaemia circulating levels of active DPP-4 
have been shown to be higher than those in healthy controls (102; 103).  
The pleiotropic effects of DPP4 inhibitors, along with the control of glucose plasma 
concentrations, represent important mechanisms of action of these drugs, among which a 
potential cardiovascular protection activity appears to be of major importance, especially in 
T2DM. DPP4 inhibitors have a protective effect on the endothelium. This protection is 
particularly useful because endothelial cells exposed to high glucose exhibit enhanced DPP4 
activity, independent of hyperosmolarity (104). DPP-4 inhibitors have anti-inflammatory and 
anti-oxidative effects (105),(106). The effects of DPP4-I on blood pressure appear more 
complex and less clear. DPP4-I administration can potentially decrease blood pressure by 
two distinct mechanisms: one at the renal level, by inhibiting sodium/hydrogen exchange, 
and the other at cardiac level, by inhibiting BNP degradation. Whether the effect of DPP4-I 
on BNP has any role on endothelial function in humans is presently unknown. However, it 
should be emphasized that very few clinical studies included reduction of blood pressure as 
a primary or prespecified end point (107). 
Intensive glucose control has been shown to provide beneficial effects on retinopathy in both 
T1D (108) and T2D (109; 110) Few experimental studies have assessed the effect of DPP4-I 
on diabetic retinopathy.  
Only three experimental studies are available on the effect of DPP4-I on diabetic neuropathy 
(107) showing  protective effects of DPP4-I.  
Ishibashi et al. reported that linagliptin inhibited the generation of reactive oxygen species 
induced by advanced glycation end products (AGEs) in endothelial cells (105). Matsubara et 
al. reported that sitagliptin improves endothelial dysfunction in association with anti-
inflammatory effects in patients with coronary artery disease and uncontrolled diabetes (111). 
Shiraki et al. reported that GLP-1 reduced TNF-α-induced oxidative stress in endothelial cells 
(106). 
Many efforts, including preclinical studies, pooled analysis of phase III clinical trials, and 
randomized controlled trials, have been devoted to test the potential cardiovascular benefits 
of DPP4-I, while their impact on microangiopathy seems to be relatively neglected. So far, 
randomized controlled trials do not support cardiovascular protective effects of DPP4-I 
(112),(113)   but studies with longer followup are likely needed to allow the effect of good 
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glycemic control achieved with DPP4-I to translate into improved cardiovascular outcomes 
(114). 
Extensive experimental data and preliminary clinical studies indicate that DPP4-I may 
improve microvascular structure and function .Whether the effects of DPP4-I are mediated by 
improved glucose control or by pleiotropic off-target actions of DPP4-I on nonincretin 
substrates remains unclear. A few hints can help answer this question with available data. 
Preclinical findings obtained in vitro and using animal models of T1D (e.g.,STZ-induced 









Treatment with DPP-4i blunts the DPP-4-mediated degradation of SDF-1α, thereby 
enhancing recruitment of EPCs to vascular beds in need of repair or expansion. 
Because SDF-1 is subject to inactivation via either DPP-4- or matrix metalloproteinase-
mediated cleavage (67; 99), DPP-4 inhibitors have been used to enhance SDF-1 activity and 






Patients. The study was approved by the Ethical Committee of the University Hospital of 
Padova and was conducted in accordance with the principles of the Declaration of Helsinki 
as revised in 2008. Informed consent was obtained from all patients. Type 2 diabetic patients 
were recruited at the outpatient clinic of the Metabolic Division, University Hospital of 
Padova. Healthy blood donor subjects were recruited anonymously from the local blood 
biobank, provided they were free from diabetes and cardiovascular disease. For diabetic 
patients, the following data were collected from the electronic outpatient clinic charts: age, 
sex, BMI, waist circumference, systolic and diastolic blood pressure. diabetes duration, 
HbA1c, lipid profile, concomitant risk factors, complications and medications. Coronary artery 
disease was defined as a past history of myocardial infarction or angina, confirmed by a 
coronary angiography showing stenosis >70% in at least one epicardial coronary vessel, or 
in the presence of a non-invasive stress test indicative of inducible myocardial ischemia. 
Peripheral arterial disease was defined as claudication, rest pain, or ischemic diabetic foot 
confirmed by an angiographic or ultrasound examination. Cerebrovascular disease was 
defined as a past history of stroke or evidence of carotid artery stenosis >30% at a 
ultrasound examination. Retinopathy was defined based on digital funduscopic photography 
scored remotely by expert ophthalmologists. Nephropathy was defined as overt 
macroalbuminuria (urinary albumin/creatinin ratio [ACR]>300 mg/g) or as chronic renal failure 
(estimated glomerular filtration rate [eGFR]<60 ml/min/1.73 m2). As the 2.5 mg renal dose-
adjusted formulation of Saxagliptin was not yet commercially available in Italy when the study 
was performed, none of the patients in the in vivo study had chronic renal failure. Data on 
medications were also collected. For the in vivo angiogenesis assay, patients on Saxagliptin 
treatment (n=5) for >4 months and patients on other, non-incretinergic, regimen (n=5) were 
enrolled. As treatment had been previously decided on clinical ground and was not assigned 
by the investigators, this did not represent a clinical trial and was not registered as such. 
 
Culture of pro-angiogenic cells (PACs) and functional assessment. PBMCs were 
isolated by density gradient centrifugation with Histopaque-1077. Cells were plated on 
human fibronectin-coated culture dishes and maintained in endothelial cell basal medium-2 
(EBM-2). The medium was supplemented with EGM-2 MV SingleQuots containing FBS (5%), 
human VEGF-1, human fibroblast growth factor-2 (FGF-2), human epidermal growth factor 
(EGF), insulin-like growth factor-1 (IGF-1), and ascorbic acid. After 4 days in culture, 
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nonadherent cells were removed by washing with PBS, new medium was applied, and the 
cells were maintained through day 7 cultured with or without Saxagliptin (Saxa, DPP-4 
inhibitor) and with or without SDF-1α. 
PACs obtained after 7 days of culture without stimuli were immunophenotyped by 
fluorescence microscopy (Leica DM 6000B) for the ability to uptake AcLDL and bind FITC-
Ulex europaeus agglutinin Lectin. Adherent cells were first incubated with Dil-acLDL for 1h, 
then counterstained with FITC-Lectin and  fixed in 2% paraformaldehyde. Images were 
acquired with the manufacturer’s software, and assembled using Adobe Photoshop. 
In separate experiments, PACs were cultured from unselected PBMCs of healthy controls in 
the presence of Saxagliptin and/or SDF-1α and, at the end of the 7 day culture period, CD14+ 
PACs were separated from CD14- PACs using the MS Column and MiniMACS Separator 
(Miltenyi Biotec). Then, functional assays and gene expression were analyzed separately for 
CD14+ and CD14- PACs. 
Adhesion assay. A monolayer of human umbilical vein endothelial cells (HUVECs) was 
prepared 48 hours before the assay by plating 2×105 cells (passage 5 to 8) in each well of 
24-well plate. PACs were labelled with CMTMR  and 1×105 cells were added to each well 
and incubated for 3 hours at 37°C. Non-attached cells were gently removed with PBS, and 
adherent PACs were fixed with 4% paraformaldehyde and counted in 10 randomly selected 
field.  
Matrigel Tubule Assay. Matrigel (Sigma-Aldrich) was thawed and placed in 96-well plate at 
room temperature for 30 minutes to allow solidification. PACs (3×103) were co-plated with 
1.5×104 human umbilical vein endothelial cells (HUVECs) and incubated at 37°C for 24 
hours. The 5:1 HUVECs/PACs ration was chosen based on a preliminary dose-response 
experiments (not shown), which showed a suppressive effect of higher ratios on tube 
formation. Tubule formation was defined as a structure exhibiting a length 4 times its width. 
The length and the number of tubules was determined in 10 randomly selected fields. 
In separate experiments performed to analyze the physical location of PACs co-cultured with 
HUVECs in the Matrigel tubule assay, PACs were red-labelled with the fluorescent dye Cell-
Tracker Orange CMTMR (Life Technologies). 
Migration assay. Cell migratory assays were performed using Transwell chambers with filter 
membranes of 3 mm pore size. Transwell chambers were inserted into the plate wells. PACs 
were seeded into the upper chamber (104 cells per well in serum-free medium) in either the 
absence or the presence of SDF-1α at 37°C. At the end of the assay, 3 hours later, PACs 
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migrated in the lower compartment were collected and counted using the flow cytometer. 
Results are reported as ratio of the number of migrated cells and non migrated cells. 
 
Flow cytometry and immunomagnetic cell sorting. For the characterization of PACs, cells 
were detached using EDTA and scraping. Cells were labelled with mouse anti-human 
PerCP-Cy5.5 CD45 (BD Pharmingen, cat# 552724), PE  KDR (R&D Systems, cat# 
FAB357P), FITC CD68 (Dako Cytomation, cat#F7135), APC CD34 (BD Pharmingen, cat# 
345804), PE CD14 (Beckman Coulter, cat# A07764), FITC CD26 (BD Pharmingen, cat# 
555436), FITC CD31 (BD Pharmingen, cat# 555445). Events were acquired using a FACS 
Canto instrument (BD), after morphological gating in the SSC vs FSC plot. Al least 105 
events were acquired for each analysis. 
PACs treated with and without Saxagliptin and/or SDF-1α for 7 days were trypsinized into 
conical tubes, washed twice with PBS and fixed in 70% ice-cold ethanol. For DNA analysis, 
cells were centrifuged at 200 g for 10 min at 4°C and washed twice with PBS. For cell cycle 
analysis, after incubation at 37°C in the dark for 15 min, DNA content of the nuclei was 
determined by staining nuclear DNA with propidium iodide solution (50 μg/mL, sigma, USA) 
containing 50 μg/mL ribonuclease A. The DNA content was measured by a flow cytometry 
(FacsCanto) and scored.  
For immunomagnetic selection of CD14pos and CD14neg cells from the initial PBMC 
population for PACs culture, we used the MS Column and MiniMACS Separator (Miltenyi 
Biotec). After isolation of PBMCs, cells were centifugated at 300 g for 10 minutes. The cell 
pellets were resuspended in 80 μL of buffer (MACS buffer), 20 μl of CD14 MicroBeads  per 
107 total cells were added. After 30 minutes in the refrigerator, cells was washed by adding 
MACS buffer and resuspended in 500 μL of buffer. The magnetic separation was performed 
as described by the manufactures. 
Determination of DPP-4 activity. DPP-4 activity was determined in conditioned medium or 
cell extracts from cell cultures using the DPP-4 drug discovery Kit (Enzo Life Sciences, 
Farmingdale, NY, USA) with the Gly-Pro-para-nitroaniline (pNA) chromogenic substrate, 
according to the manufacturer's instructions. 
 
Gene expression analysis. After 7 days of culture total RNA was extracted from PACs 
using RNeasy kit (Qiagen), following the manufacturer’s protocol. RNA quantity was 
determined on a Nanodrop Spectrometer (termo Fisher scientific  Inc) (using 1 OD260 = 40 
µg RNA). A260/A280 ratios were also calculated for each sample. RNA was reverse 
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transcribed to generate cDNA using the First-Strand cDNA Synthesis Kit from Invitrogen 
following the manufacturer’s protocol. Samples were mixed by vortexing and briefly 
centrifuged and denaturated by incubation for 5 minutes at 70°C to prevent secondary 
structures of RNA. Samples were incubated on ice for 2 minutes to allow the primers to align. 
Gene-specific primer pairs were designed using Primer-BLAST (NCBI) and were each 
validated prior to use by gradient PCR and gel analysis to test for optimal annealing 
temperature, reaction efficiency and specificity (Table 1). Duplicates of sample cDNA were 
then amplified on the 7900HT Fast Real-Time PCR System (Applied Biosystems) using the 
Fast SYBR Green RT-PCR kit (Applied Biosystems) in 96-wells plates (micro amp optical, 
Applied Biosystems). Expression data were normalized to the mean of housekeeping gene to 
control the variability in expression levels and were analyzed using the 2-∆CT method. 
 
Mouse colony forming assay. Hematopoietic colonies were grown from unfractioned bone 
marrow cells of C57Bl/6 mice and quantified using the Methocult system (Stem Cells inc. 
Vancouver, Canada). For all experiments using animals, the ‘Principles of laboratory animal 
care’ (NIH publication no. 85–23, revised 1985; 
http://grants1.nih.gov/grants/olaw/references/phspol.htm) as well as specific national laws 
were followed. 
 
Spheroid assay. For preparation of methocell, 6 g of methyl-cellulose together with a 
magnetic stir bar were autoclaved in a 500 ml flask. Afterwards, 250 ml of 60°C basal EBM 
medium was added under sterile conditions and the suspension was stirred at 60°C for 40 
min. Additional 250 ml of basal EBM medium were added and the solution was stirred at 4°C 
overnight. 50 ml portion of the solution were centrifuged for 2 h at 4000 rpm at room 
temperature. The highly viscose soluble fraction was separated from insoluble residue and 
was stored at 4°C. The following protocol was applied for the spheroid assay: 48,000 
HUVEC were mixed with 6 ml of methocoel / HUVEC medium and seeded as 100 µl drops in 
a 96-well U-bottom dish using a multipette. The cells were incubated for 24 h in an incubator 
to form spheroids. The day after, spheroids were collected, centrifuged and the spheroid 
pellet was mixed with methocoel-mix The collagen gel was prepared on ice and 500 µl of 
collagen gel were added to the spheroid / methocoel solution, mixed by pipetting and seeded 
on a 24-well culture dish for 30 min in an incubator. The spheroids were cultured for 24 h at 
37°C and 5% CO2. Spheroids were fixed with formaldehyde. For quantification, 10 spheroids 




In vivo angiogenesis assays. To gather information on the presence of functional 
circulating PACs and how they are modulated by Saxagliptin in type 2 diabetic subjects, we 
used the in vivo Matrigel plug angiogenesis assay with patients’ own PBMC. Briefly, PBMC 
were isolated with Histopaque (Sigma-Aldrich). Cell count and viability were assayed with an 
automated BioRad TC20 cell counter. Then, 3 x 106 PBMC were resuspended in 500 μL 
phenol-free Matrigel (BD, cat no. 356237) and implanted subcutaneously into the dorsum of 
immunodeficient RAG-2/gamma(c) double knock-out mice (in-house colony). Experiments 
involving animals were performed according to national guidelines and according to the 
‘Principles of laboratory animal care’ (NIH publication no. 85–23, revised 1985; 
http://grants1.nih.gov/grants/olaw/references/phspol.htm). The experiment was performed 
with PBMC of n=5 type 2 diabetic patients on Saxaglipthin therapy (>4 months) and n=5 type 
2 diabetic patients on non-incretinergic therapy. Mice were anesthetized with 100 mg/ml 
Ketamine HCL and 20 mg/ml Xylazine. To minimize variability, the same mouse received 
Matrigel plugs from a Saxagliptin-treated and a control patient. Plugs were explanted 10 days 
later for macroscopic inspection, histology (H&E staining), and determination of the 
hemoglobin/protein content ratio (Drabkin’s solution and Bredford reagent respectively, 
Sigma-Aldrich), which is as a surrogate of perfusion. 
In addition to the traditional Matrigel plug assay, we also used the Directed In Vivo 
Angiogenesis Assay (DIVAA, Amsbio, Abingdon, UK), which employs semi-closed small 
silicone cylinders called “angioreactors”, filled with Matrigel with or without a growth factor 
cocktail (fibroblast growth factor [FGF] + vascular endothelial growth factor [VEGF]) 
specifically design to stimulate vascular invasion. Angioreactors containing patients’ own 
PBMC were implanted subcutaneously in the dorsal flanks of RAG-2/gamma(c) double 
knock-out mice. Compared to the traditional plug assay, the sleek design of angioreactors 
provides a standardized platform for reproducible and quantifiable in vivo angiogenesis 
assays and prevents assay errors due to absorption of Matrigel by the mouse. In the present 
protocol, each anaesthesized mouse received implantation of 4 angioreactors, 2 containing 
cells from Saxagliptin-treated patients and 2 containing cells from control patients, each with 
or without adding growth factors. Angioreactor tubes were explanted 10 days later for gross 
inspection of vascular invasion and determination of perfusion by FITC Lectin detection, 
according to the manufacturer’s protocol. As fluorescence labelled Griffonia simplicifolia 
Lectin binds to alpha-D-galactosyl and N-acetyl galactosaminyl groups on the surface of 
endothelial cells, Lectin content is a measure of angioreactor tube vascular invasion. 
 
Statistical analysis. Data are presented as mean ± standard error, or as percentage where 
appropriate. Normal distribution of the variables under investigation was verified using the 
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Kolmogorov-Smirnov test. Non normal variables were log transformed. Comparison between 
means was performed with the unpaired 2-tail Student’s t test. Comparison between more 
than 2 groups was performed with ANOVA. The Bonferroni correction was used to account 
for multiple testing, where appropriate. Frequencies were compared using the Chi square 






Characterization of cultured pro-angiogenic cells. Pro-angiogenic cells (PACs) cultured 
from human PBMCs constitute a heterogenous population composed mostly of CD45+ 
lymphocytes and monocyte/macrophage lineage cells, plus a small population of 
stem/progenitor cells, possibly including EPCs (57). Accordingly, we found that PACs culture 
was comprised of i) small cells in the lymphocytic morphologic (FSC vs SSC) gate, some of 
which expressed KDR (21±3%) and CD31 (36±5%) and can correspond to angiogenic T cells 
present in PACs / early EPCs culture (116); ii) larger mononuclear cells expressing CD14, 
CD68, and CD31, likely belonging to the monocyte-macrophage population. The 
monocytic/lymphocytic cell ratio was 2.2±0.1 and fairly constant throughout experiments. As 
expected, expression of the stem/progenitor cell marker CD34 was low (Figure 12A). These 
data indicate that cells used in subsequent experiments correspond to the PAC phenotype 
already described in the literature. Cultured PACs were also characterized by the double 
positivity for the (non-unequivocal) endothelial markers acetylated LDL uptake and Ulex-
Lectin binding (Figure 12B). Interestingly, the fraction of acLDL+Lectin+ cells in the PACs 
culture was significantly lower in T2D compared to healthy controls (30.8±0.8% vs 
36.0±0.1%; p=0.003). There were no differences in the proportion of lymphocytic and 
monocytic cells in PACs cultures of T2D versus healthy subjects 
 
Figure 12. Phenotypic  characterization  of  cultured  PACs. A)  PACs were  characterized  for  surface marker 
expression  by  flow  cytometry.  In  the  side  scatted  (SSC)  versus  forward  scatter  (FSC)  morphologic  plot, 









In vitro DPP-4 activity sources and effective enzymatic inhibition. We preliminarily 
tested the non-pharmacologic DPP-4 inhibitor Diprotin-A and several concentrations of the 
clinically available inhibitor Saxagliptin on DPP-4 activity in the conditioned medium obtained 
from HUVEC cultures. We found that 0.5 μM Saxagliptin was sufficient to reach maximal in 
vitro DPP-4 inhibition (~70%), which was equal to the degree of inhibition achieved using 
standard Diprotin-A concentrations (Figure 13A). The 0.5 μM Saxagliptin concentration, 
which has the same order of magnitude as the Cmax obtained in vivo in humans after a 5 mg 
oral dose (0.1-0.3 μM), was chosen for subsequent experiments.  
DPP-4 exists as a soluble secreted protein or a membrane-bound isoform, which also plays 
a role in signal transduction and adenosine metabolism (117). In cultured PACs, membrane 
DPP-4 (CD26) expression was restricted to a subpopulation of lymphocytes (~50% of the 
lymphocyte gate), whereas larger monocytic cells were CD26-negative (Figure 13B). By 
using PACs cultured from CD14pos or CD14neg cells, we compared soluble (cell-free 
conditioned medium) and cellular (cell extracts) DPP-4 activity and the effect of Saxagliptin. 
Soluble DPP-4 activity was 3-5 fold higher compared to cellular DPP-4 activity regardless of 
whether CD14pos or CD14neg cells were present in the culture, and was inhibited >50% by 
Saxagliptin. As expected, cellular DPP-4 activity was higher in CD14neg(CD26+) cells 
compared to CD14pos(CD26-) cells and it was inhibited >50% by Saxagliptin. The DPP-4 
activity of CD14pos cells, which do not express significant amounts of membrane CD26, can 
be explained by residual DPP activity provided by isoforms other than DPP-4 (e.g. DPP-8 
and -9) (118), that are partly inhibited by Saxagliptin (Figure 13C). These data indicate that, 
in PAC cultures, soluble activity is higher than cellular activity of DPP-4, the latter being 
mostly attributed to lymphocytes than to monocytic cells, while both soluble and cellular 




Figure 13. In vitro DPP‐4  inhibition. A) Degrees of soluble DPP‐4  inhibition  in  the conditioned medium by 
treatment of HUVECs with Diprotin‐A  (DPA) or different Saxagliptin concentrations, relative to  the untreated 
control condition (CTRL). The experiment was performed in triplicate. * p<0.05 for ANOVA test. B) Expression 
of membrane DPP‐4  (CD26)  on monocytic  (MONOs)  and  lymphocytic  (LYMPHs)  cells,  identified  by  the  side 
scatted  (SSC)  versus  forward  scatter  (FSC) morphologic  plot  of  PACs  culture.  C)  Soluble  and  cellular DPP‐4 










Functional effects of Saxagliptin on PACs from healthy controls and type 2 diabetic 
patients. We obtained PBMCs from n=20 healthy blood donors (50% males, aged 52±3) free 
of diabetes and cardiovascular disease, and n=20 patients with T2D (Table 2). We tested in 
vitro the ability of Saxagliptin 0.5 μM to modify PACs properties, such as clonogenesis and 
proliferation, adhesion, migration and tubulization. Given that DPP-4 inhibition is supposed to 
affect PACs by protecting SDF-1α (and other substrates) from enzymatic inactivation (100), 
we evaluated the effects of Saxagliptin with and without SDF-1α supplementation.  
 
Gene expression. First, we determined the expression of genes related to PACs function and 
survival. In PACs isolated from T2D patients compared to healthy control PACs, we found 
significantly altered expression of BCL2, CDKN1A, VCAM1, ICAM1, ITGB2 and DPP4 
(Figure 14A). Importantly, as previously noted (119), DPP4 gene expression was markedly 
increased in diabetic PACs, providing a rationale for pharmacologic DPP-4 inhibition. 
Expression of the selected genes in the entire PACs culture was unaffected by treatment 
with Saxagliptin and/or SDF-1α (not shown). In separated CD14+ monocytic PACs compared 
to CD14- lymphocytic PACs, we found lower expression of BCL2 and higher expression of 
CKDN1A and VCAM1 at baseline (Figure 14B). In addition, Saxagliptin treatment increased 
BCL2, CDKN1A, ITGB2 and VCAM1 expression in CD14+ PACs, while the effect was 






reported  relative  to  the housekeeping gene as 2ΔCT. Note  the  logarithmic  scale. *p<0.05 T2D  versus Ctrl. B) 
Expression  of  a  selected  number  of  genes  found  to  be  differentially  expressed  in  (A) was  tested  in  CD14+ 






Proliferation and clonogenesis. While the culture of PACs from healthy controls yielded 
several rounded cell colonies in addition to interspersed cells, colonies were rarely seen 
during culture of PACs from T2D  (Figure 15A). As expected from a PACs culture, the 
proliferation rate was low (3-5%). Treatment with Saxagliptin alone, but not in combination 
with SDF-1α, doubled the percentage of cells in the S+G2/M phases compared to the control 
 45 
 
condition only in healthy subjects’ PACs (Figure 15B). It has been previously reported that 
DPP-4 cleaves and inactivates several hematopoietic growth factors, suggesting that DPP-4 
inhibition may sustain hematopoiesis (120). Saxagliptin and/or SDF-1α did not restore colony 
formation during PAC culture from T2D PBMCs, but tended to increase the number of 
colonies of PACs cultured from healthy controls. Furthermore, using the methylcellulose 
mouse bone marrow hematopoietic colony assay (Figure 15C), we report that treatment with 
Saxagliptin + SDF-1α was indeed able to increase the total number of hematopoietic 
colonies. A breakdown analysis showed that treatment with Saxagliptin + SDF-1α induced 
consistent trend increases of most colony types, especially granulocytes and macrophages 
(Figure 15D). These data indicate that, unlike in diabetic cells, in non diabetic cells 
Saxagliptin may favour proliferation, while the co-treatment with SDF-1α promotes 
hematopoietic clonogenesis. Differences in the proliferative response between healthy 
control and diabetic PACs may be related to the differential baseline expression of genes 
regulating cell cycle and survival, such as CDKN1A (encoding p21) and BCL2 (Figure 14). 
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of  murine  hematopoietic  colonies  exposed  to  Saxagliptin  with  or  without  SDF‐1α  supplementation.  D) 





Adhesion. Adhesion of PACs to mature endothelial cells represents an important step for the 
pro-angiogenic and vascular repairing activity of PACs. We thus tested adhesion of PACs to 
HUVECs in vitro and found that the number of adherent PACs was unaffected by treatment 
in healthy controls, while Saxagliptin significantly increased adhesion of T2D PACs in the 
presence of SDF-1α (Figure 16A, B). The significantly lower baseline adhesive capacity of 
diabetic PACs compare to control PACs and the differential response to Saxagliptin + SDF-
1α may be related to the different baseline expression of adhesion molecule genes, such as 
ICAM1, VCAM1 and ITGB2 (Figure 14).  
We used this assay to understand the relative contribution of membrane bound DPP-4 
(CD26), which is expressed on CD14neg, but not on CD14pos PACs. Therefore, we cultured 
PACs from healthy controls starting from immunomagnetically purified populations of 
CD14pos and CD14neg cells. We found that Saxagliptin reduced adhesion by CD14posCD26neg 
cells and increased adhesion by CD14negCD26pos cells (Figure 16C). This indicates that 
inhibition of soluble DPP-4 only (as in cultures of CD14pos cells) and inhibition of both 
isoforms (as in cultures of CD14neg cells) can have opposing effects on PACs function and 
explains, at least in part, why Saxagliptin has modest or no overall net effect on the 
heterogeneous PACs culture. In addition, to better understand which is the saxagliptin-
responsive cell type in the heterogeneous PACs culture, we separated CD14+ from CD14- 
PACs cultured from unselected PBMCs in the presence of Saxagliptin and/or SDF-1α. We 
found that the adhesive capacity of CD14+ monocytic PACs was significantly higher than that 








patients  and  healthy  controls  exposed  to  Saxagliptin  with  or  without  SDF‐1α  supplementation.  B) 
Quantification  of  adherent  PACs  from  type  2  diabetic  (T2D)  and  healthy  (Ctrl)  subjects  in  the  untreated 
condition and according to the treatment with Saxagliptin, with or without SDF‐1α supplementation. *p<0.05 
versus  the  untreated  control  condition  (Ctrl).  C)  Effects  of  Saxagliptin  on  cell  adhesion was  determined  in 
cultures  of  healthy  PACs  obtained  from  pre‐selected  CD14+  and  CD14‐  cells.  *p<0.05  versus  the  untreated 
control  condition  (Ctrl). D) Baseline  adhesion  and  effects of  Saxagliptin  +/‐  SDF‐1α was  tested  in  separated 
CD14+  and  CD14‐  PACs,  after  cells were  cultured  from unselected  PBMCs.  *p<0.05  in  CD14+  vs  CD14‐  cells; 
†p<0.05 versus the control condition. 
 
Migration. Migration of PACs was assessed using a transwell assay, with the chemokine 
SDF-1α being the prototypical positive control (98). We found that the percentage of 
migration was increased by SDF-1α using both healthy and diabetic PACs, whereas 
Saxagliptin alone or in combination with SDF-1α did not affect migration of both control and 
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diabetic PACs (Figure 17). It should be noted that the absolute numbers of migrating cells in 
this system was low, thus limiting the chance of reporting small effects as significant.  
 




Tube formation. Tubulization by HUVECs co-cultured with PACs was assessed using the 2D 
Matrigel assay (Figure 18A). It is well known that PACs do not spontaneously form tubules in 
2D Matrigel, but can sustain tubulogenesis by mature endothelial cells (57). We found that 
only T2D PACs treated with Saxagliptin + SDF-1α were able to increase tube length 
formation by HUVECs, while there was no effect on healthy PACs (Figure 18B-C). The 
number of branching points was not significantly different in T2D compared to controls and 
was unaffected by treatments (not shown). In addition, we evaluated the tube supportive 
capacity of CD14+ PACs versus CD14- PACs and how  they are affected by treatments. We 
found that HUVECs co-cultured with CD14+ monocytic PACs showed increased tube 
formation compared to co-culture with CD14- lymphocytic PACs. Moreover, tube formation by 
HUVECs/CD14+ PACs was significantly increased by Saxagliptin treatment compared to the 
control condition (Figure 18D). Most of labelled PACs co-cultured with HUVECs remained 
located in cellular islands at tube intersections, while only some contributed physically to tube 
formation. No difference was seen in the percentages of tubes bearing integrated CD14+ 
(15±4%) versus CD14- PACs (12±2%; p=0.41) (Figure 18E). 
Finally, as the tube assay is strictly dependent on the cooperation between HUVECs and 
PACs, we explored the effect of Saxagliptin on in vitro angiogenesis assays of isolated 


































































sprouting assay, Saxagliptin modestly but significantly reduced in vitro angiogenesis by 
mature endothelial cells (Figure 19A, B). 
 
 
Figure 18. Effects of Saxagliptin on migration and tubulisation of PACs. A) Representative microphotographs 
of tube formation  in 2D Matrigel by HUVECs co‐cultured with PACs from type 2 diabetic patients and healthy 




tube  length  formation by HUVECs  alone  and HUVECs  co‐incubated with CD14+ or CD14‐ PACs  from healthy 
controls.  *p<0.05  in  CD14+  vs  CD14‐  cells;  †p<0.05  versus  the  control  condition.  E)  Red‐labelled  PACs  co‐




In vivo effect of Saxagliptin on angiogenesis induced by circulating cells. To assess 
the relevance of the pro-angiogenic effects of Saxagliptin on circulating PACs compared to 
the possible anti-angiogenic effects on mature ECs, we used in vivo Matrigel assays. First, 
PBMCs from T2D treated with Saxagliptin (n=5) and PBMCs from T2D patients on non-
incretinergic therapy (n=5; see Table 2) were embedded into Matrigel plugs and implanted 
subcutaneously into immunodeficient mice. Angiogenesis in this model is mediated by the 
cooperation between the intraplug cells (the circulating source of PACs) and mouse ECs 
invading the plug. We found a non-significant increase in vascular plug invasion and 
hemoglobin content (a surrogate of plug vascularization) in plugs containing PBMC from 
Saxagliptin-treated compared to those from untreated diabetic patients (Figure 19C). To 
further address this issue, we used the Directed In Vivo Angiogenesis Assay (DIVAA), which 
allows a more reproducible quantification of in vivo angiogenesis. DIVAA angioreactor tubes 
were implanted with cells obtained from saxagliptin-treated and non incretin drug-treated 
T2D patients, with or without growth factors (GF) that stimulate angiogenesis. During the 
course of the assay, implant grade silicone cylinders closed at one end, called angioreactors, 
are filled with 20 µl of Trevigen's basement membrane extract (BME) premixed with or 
without angiogenesis modulating factors. These angioreactors are then implanted 
subcutaneously in the dorsal flanks of nude mice. If filled with angiogenic factors, vascular 
endothelial cells migrate into, and proliferate in the BME to form vessels in the angioreactor. 
As early as nine days post-implantation, there are enough cells to determine an effective 
dose response to angiogenic factors. We did not find significant differences in the Lectin 
content (a proxy of perfusion in DIVAA experiments) in tubes containing cells from 
saxagliptin-treated patients versus controls in either the presence or absence of GF. 
However, the difference between Lectin content in tubes with and without GF, indicative of 
the ability of GF to increase PBMC-mediated angiogenesis in each patient, was significantly 










vivo  angiogenesis  in Matrigel  plugs  by  PBMCs  isolated  from  Saxagliptin‐treated  and  non‐incretinergic  drug 
treated type 2 diabetic patients (n=5/group). Representative figures, as well as quantification of Hb content are 
shown.  D)  PBMC  from  Saxagliptin‐treated  and  non‐incretinergic  drug  treated  type  2  diabetic  patients 
(n=5/group) were also used for the Directed In Vivo Angiogenesis Assay (DIVAA) using angioreactor tubes with 
(+) and without (‐) growth factors (GF). After visual inspection, Lectin content was determined as an indicator 






In the present study, we show that DPP-4 inhibition with Saxagliptin reverses PACs 
dysfunction associated with T2D in vitro and improves inducible angiogenesis by patients’ 
cells in vivo. We have previously shown that DPP-4 inhibition increases circulating EPCs in a 
similar population of T2D subjects (100). Herein, we add to those findings showing that, not 
only the level, but also the function of vascular protective cells can be improved by DPP-4 
inhibition.  
PACs derived from PBMC cultures differ from EPCs quantified ex vivo by flow cytometry, as 
they are composed of a heterogenous population of angiogenic T cells and monocyte-
macrophages, plus a small population of progenitor cells (57). The pro-angiogenic and 
vascular repair capacity of human PACs has been consistently demonstrated in pre-clinical 
studies (121; 122). In addition, autologous administration of bone marrow derived PACs was 
shown to improve left ventricular ejection fraction in patients with acute myocardial infarction 
(123), confirming the protective cardiovascular effects of these cells in humans. The 
mechanisms whereby PACs achieve vascular protection in vivo are not entirely clear, but 
data suggest that they are mainly derived from an intense paracrine activity, rather than 
definite endothelial differentiation and integration (77). Indeed, although a significant 
ontologic overlap between the endothelium and hematopoietic cells exists in the embryo 
(124), epigenetic brakes prevent blood-derived PACs to differentiate into mature endothelium 
in adulthood (125). The heterogeneous composition of PACs culture could be seen as a limit 
to the interpretation of the present findings. However, it should be noted that late EPCs and 
ECFC can be only stochastically isolated from peripheral blood of diseased subjects (57), 
thus limiting reproducibility of the findings. Whether PACs mainly represent an in vitro 
artefact or they also exist in vivo is a matter of debate, although the discovery of the so-
called haemogenic endothelium suggest that endothelial-hematopoietic overlaps can occur 
also in adulthood (124). Hemogenic endothelial cells are rare, differentiated vascular 
endothelial cells that generate hematopoietic (blood) cells during embryogenesis. The main 
function of hemogenic endothelium is to generate definitive hematopoietic precursors and 
stem cells (126). 
Several authors have reported that diabetes induces PACs dysfunction, through epigenetic 
changes (127), eNOS modulation (128), and humoral factors (129). We herein confirm that 
PACs isolated from T2D have impaired differentiation, clonogenesis and adhesion compared 
to PACs isolated from healthy controls. This was associated with changes in the expression 
of genes related to adhesion and regulation of cell cycle. Such differences, however, cannot 
be directly attributed to diabetes per se, because T2D patients were also older than controls 
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and had additional cardiovascular risk factors. The rationale for including healthy controls 
instead of matched non-diabetic patients was to assess the effects of Saxagliptin within each 
group and understand whether DPP-4 inhibition influences both diseased and healthy PACs. 
Interestingly, we found that, with the exception of proliferation, only PACs from T2D patients 
improved their function after treatment with Saxagliptin. This can be attributed to the marked 
upregulation of DPP4 gene expression in diabetic PACs. We have previously shown that 
DPP-4 activity is increased in serum/plasma of T2D compared to non-diabetic patients and is 
not directly related to glucose control (119). DPP-4 exists as either a soluble or membrane 
bound (cellular, CD26) isoform and the relative contribution of the two to the total DPP-4 
activity and its biological effects were previously unknown. We show that soluble DPP-4 
activity is higher than cellular DPP-4 activity, which is restricted to a lymphocyte 
subpopulation. This is particularly important in cultures of PACs, which are composed of 
angiogenic T cells and endothelial-like monocyte-macrophages. Indeed, we found that, 
though Saxagliptin did not significantly affect adhesion of healthy PACs, when PACs were 
isolated starting from CD14+(CD26/DPP-4-) cells or CD14-(CD26/DPP-4+) cells, the effects of 
Saxagliptin on adhesion were opposite. In addition, among the heterogeneous PACs 
population, CD14+ monocytic PACs compared to CD14- lymphocytic PACs showed higher 
functionality at baseline and were much more responsive to Saxagliptin-induced gene 
expression changes and stimulation of adhesion and tube supporting capacity. While such 
differences can be the result of cell-type specific responses to Saxagliptin, it is possible that 
cellular DPP-4 inhibition exerts different effects compared to soluble DPP-4 inhibition. While 
membrane bound DPP-4 may transduce intracellular signals and is a cofactor of adenosine 
deaminase (117), secreted DPP-4 is supposed to act mainly through cleavage of soluble 
mediators. Indeed, we found that Saxagliptin improved whole PACs function only in the 
presence of SDF-1α supplementation, whereas Saxagliptin alone or SDF-1α alone less 
effective. Based on the low SDF-1α concentrations in the medium (fg/ml) compared to the 
high DPP-4 expression / activity, it is rationale that only simultaneous SDF-1α 
supplementation and DPP-4 inhibition provided significant biological effects, a finding that 
supports the mechanistic theory whereby DPP-4i affects PACs by protecting SDF-1α (and 
possibly other factors) from enzymatic degradation. In addition to improving PACs function, 
DPP-4 inhibition also mobilizes EPCs via SDF-1α (100). This synergistic effect is expected to 
promote favourable outcomes in several diabetic complications (130), including wound 
healing  (131; 132). 
Fadini et al found [puoi dire “our group previously found”] a negative correlation between 
DPP-4 activity and plasma SDF-1α concentrations. Plasma DPP-4 activity was directly 
correlated to the BM/PB ratio of CD34+ cells, supporting the hypothesis that DPP-4 regulates 
CD34+ cell mobilization. They first analyzed DPP-4 activity in rats and found increased 
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activity in PB and decreased activity in BM of diabetic compared to non-diabetic rats. Then, 
they tested the bone marrow progenitor cell mobilization in wild type and DPP-4 deficient rats 
after either G-CSF stimulation or hind limb ischemia. This study, by combining a clinical data-
driven discovery approach with animal models, shows that altered mobilization of 
stem/progenitor cells is associated with a high cardiovascular risk profile and, in the setting of 
diabetes, is driven by a tissue-specific DPP-4 dysregulation (118). 
In contrast to the positive effects exerted by Saxagliptin + SDF-1α on T2D PACs, Saxagliptin 
+/- SDF-1α did not affect function of healthy control PACs when evaluated in the entire 
population, but differentially affected function of CD14+ monocytic versus CD14- lymphocytic 
cells. Saxagliptin also reduced angiogenesis by mature endothelial cells in vitro, suggesting 
cell-type specific effects. Therefore, to understand the overall net effects of Saxagliptin on 
angiogenesis in vivo, we used PBMCs isolated from Saxagliptin-treated and from control 
T2D patients treated with non-incretinergic drug. The Matrigel plug assay showed non-
significantly higher perfusion obtained with Saxagliptin-treated compared to control cells. As 
this assay has wide variability depending on how the plug develops and is adsorbed in the 
mouse, we also used the more reliable and quantitative Directed In Vivo Angiogenesis Assay 
(DIVAATM). DIVAA is the first in vivo system for the study of angiogenesis that provides 
quantitative and reproducible results (133). The sleek design of the angioreactor provides a 
standardized platform for reproducible and quantifiable in vivo angiogenesis assays. 
Compared to the plug assay, the angioreactor prevents assay errors due to absorption of 
BME by the mouse. In addition, the angioreactor uses only a fraction of the materials 
conserving both BME and test compounds used, and up to four angioreactors may be 
implanted in each mouse, giving more data for analysis. 
We found that the extent to which growth factors (VEGF + FGF) increased vascular invasion 
of the angioreactor was significantly higher for Saxagliptin-treated compared to control cells. 
This suggests that Saxagliptin increases the ability of circulating cells to respond to pro-





Reversal of T2D PACs dysfunction and stimulation of inducible angiogenesis may translate 
in a microvascular (134) and cardiovascular protective activity of DPP-4i. While pooled data 
from short-term phase III randomized clinical trials in selected T2D patients showed potential 
cardiovascular benefit of Saxagliptin (135), the Saxagliptin Assessment of Vascular 
Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) clinical trial, conducted on 
>16,000 T2D patients with a history or risk factors for cardiovascular events, showed a 
neutral effect of Saxagliptin on the rate of ischemic events (136). However, this event-driven 
study was terminated after just a median follow-up of 2.1 years, thus limiting the chance that 
protective effects of Saxagliptin translated into an event rate reduction. So far, experimental 
pre-clinical and clinical findings widely argue for potential cardiovascular protection by DPP-4 
inhibition. The observation that Saxagliptin restores the function of PACs from T2D patients 
represents an additional step toward a better understanding of the pathobiology of DPP-4 in 
diabetes. PACs function can be restored by glucose normalization, as shown in islet-
transplated type 1 diabetic patients (137). Therefore, Saxagliptin may also impact PACs pro-
angiogenic activity by improving glucose control (138). As HbA1c was only slightly and not 
significantly lower in Saxagliptin-treated patients compared to patients on non-incretinergic 
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Table 1. Primer sequences for real time PCR analysis. 
 




β-Actin AGAGCTACGAGCTGCCTGAC GGATGCCACAGGACTCCA 
Bcl2 GTGGTGCAACCCACCACTTC GGCAGGCATGTTGACTTCAC 
CDKN1A AGCTATGACCTCAAGGACAC CGGCGTTTGGAGTGGTAGAA 
CXCR4 GAAACCCTCAGCGTCTCAGT AGTAGTGGGCTAAGGGCACA 
IL8 TGTGAAGGTGCAGTTTTGCCA CCCAGTTTTCCTTGGGGTCC 
MCP1 ACAACACGCTGTTCGGCTA GGGGCATTGATTGCATCTGG 
DPP4 ACGTGAAGCAATGGAGGCAT GTGACCATGTGACCCACTGT 
MMP9 AGAGCTACGAGCTGCCTGAC TGGGTGTAGAGTCTCTCGCT 
TGF alpha TGAAAGCATGATCCGGGACG TGGGGAACTCTTCCCTCTGG 
VCAM1 GTTTGCAGCTTCTCAAGCTTT GATGTGGTCCCCTCATTCGT 
ICAM1 TGTGACCAGCCCAAGTTGTT TGGAGTCCAGTACACGGTGA 





Table 2. Characteristics of type 2 diabetic patients included in  the study. Data are presented 
as mean ± standard error, or as percentage, where appropriate. There were no significant 
differences between the two groups of the in vivo study. 
 
Variable In vitro study In vivo study 
Saxagliptin Controls 
Number  20 5 5 
Age, years 65.2±2.3 67.4±2.6 66.1±1.1 
Sex male, % 65.0 80.0 60.0 
Risk factors    
BMI, kg/m2 30.3±2.1 29.1±1.9 28.7±2.1 
Waist circumference, cm 104.8±3.9 102.8±4.0 103.7±5.1 
Diabetes duration, years 11.3±4.2 9.8±3.6 12.4±5.3 












Hypertension, % 75.0 80.0 100.0 
Systolic blood pressure, mm Hg 138.1±3.2 137.4±4.2 140.1±3.5 
Diastolic blood pressure, mm Hg 86.7±2.7 82.4±3.8 84.5±4.6 























Smoke, % 15.0 0.0 20.0 
Complications    
Coronary artery disease, % 25.0 20.0 0.0 
Peripheral vascular disease, % 20.0 40.0 20.0 
Cerebrovascular disease, % 40.0 40.0 20.0 
Retinopathy, % 20.0 0.0 20.0 
Nephropathy, % 25.0 0.0 0.0 
eGFR<60 ml/min/1.73 mq 0.0 0.0 0.0 
Therapy    
Insulin therapy, % 50.0 0.0 20.0 
Oral therapy, % 45.0 100.0 80.0 
Diet alone, % 10.0 0.0 20.0 
ACE inhibitors / ARBs, % 80.0 80.0 80.0 
Statin, % 65.0 60.0 80.0 
 
 
 65 
 
 
  
 
 
 
 
